Oral Water Hydration to Prevent Post-Vaccination Presyncope
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02353390|
Recruitment Status : Completed
First Posted : February 2, 2015
Last Update Posted : July 7, 2016
|Condition or disease||Intervention/treatment||Phase|
|Presyncope Syncope||Other: Oral Water Hydration||Not Applicable|
Post-vaccination syncope is a rare but potentially serious adverse event in adolescents and young adults. Because few data are available regarding post-vaccination syncope, evidence regarding presyncope and syncope after blood donation provides useful insight. Based on studies of blood donors, acute water loading fifteen minutes prior to vaccination with 500 mL of water might reduce the risk of syncope. However, the degree to which hydration attenuates the risk of post-vaccination syncope or presyncope is unknown. Furthermore, little is known about the acceptability of pre-vaccination hydration to adolescents and young adults.
The objective of this study is to conduct a study to evaluate the acceptability and impact of oral hydration to prevent presyncope following vaccination in adolescents and young adults 11 through 21 years of age. The primary objectives are to determine if pre-vaccination hydration decreases the rate of presyncope in adolescents and young adults receiving at least one intra-muscular (IM) vaccine and to determine if pre-vaccination hydration is acceptable to adolescents and young adults.
This is a randomized controlled open-label study in adolescents and young adults receiving at least one IM vaccine. Vaccine administration will be part of routine care and will not be a study procedure. Adolescents and young adults 11- through 21 years of age will be eligible for participation. Minimal subject exclusion criteria will be used to best reflect how pre-vaccination hydration could be used outside of the controlled trial setting. For all primary and secondary objectives, data will be collected before and after vaccination, with data collection to be completed on the day of enrollment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1820 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Feasibility and Impact of Implementing an Oral Water Hydration Strategy to Prevent Post-Vaccination Presyncope and Syncope in Adolescents and Young Adults|
|Study Start Date :||March 2015|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||June 2016|
Active Comparator: Oral Water Hydration
Subjects will be given up to 15 minutes to drink up to 500 mL of water prior to the first IM vaccination.
Other: Oral Water Hydration
Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
No Intervention: Usual Care
Subjects will receive usual care prior to the first IM vaccination. No water or food will be offered.
- Presyncope [ Time Frame: 20 minutes ]
Sudden onset of one or more of the following symptoms or signs during the post-vaccination observation period in the clinic:
- Feeling lightheaded, like you might "pass out" or faint
- Feeling dizzy, like the room is spinning
- Feeling weak
- Feeling like your face is getting red and warm (or hot), like blushing
- Noticing any change in your vision, like spots or flickering lights, tunnel vision, or loss of vision
- Experiencing ringing in your ears, decreased hearing, or sounds seem far away
- Feeling like your heart is beating fast or hard or pounding
- Feeling hot AND sweaty
- Feeling cold AND sweaty, or "clammy"
- Feeling like you are breathing fast or hard
- Feeling like you might throw up (nausea)
- Facial flush
- Decreased interactivity (decreased level of arousal or responsiveness)
- Not Syncope
- Not due to another cause
- Not clearly present at baseline
- Acceptability of oral water hydration in the intervention group, assessed by qualitative reports in the post-vaccination observation period and response to a survey about whether they liked getting water. [ Time Frame: 20 minutes ]
- Syncope [ Time Frame: 20 minutes ]
Syncope (fainting) that occurs in an otherwise healthy person after receipt of a vaccine or during venipuncture is usually attributed to vasovagal syncope, and may occur alone (simple syncope) or may be associated with tonic-clonic movements (convulsive syncope, anoxic seizure). For the purposes of this study, we have defined syncope as: Any sudden and brief loss of consciousness or postural tone after vaccination from which recovery is spontaneous and is not attributed to another cause (e.g., anaphylaxis). For purposes of this study, cases counted as syncope must occur during the post-vaccination observation period.
Individuals that develop syncope after presyncope will be classified only as having syncope.
- Alternative Case Definition of Presyncompe [ Time Frame: 20 minutes ]In secondary analysis, the case definition of presyncope (Outcome 1) will be defined as any response of self-report of the symptoms of presyncope at a level of "somewhat," "a lot," or "extremely" compared to "none" or "a little."
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02353390
|United States, Massachusetts|
|Boston Medical Center|
|Boston, Massachusetts, United States, 02118|
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27705|
|Principal Investigator:||Alex R Kemper, MD, MPH, MS||Duke University|
|Principal Investigator:||Elizabeth D Barnett, MD||Boston University|
|Principal Investigator:||Theresa Harrington, MD||Centers for Disease Control and Prevention|